Clinical trials - Cancer Research SA

Filter By

LIDERA

Phase 3

Breast ER+/Her2- Early Stage

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Read more: Breast ER+/Her2- Early Stage
HER2CLIMB

Phase 3

Open and recruiting

Breast Her2+ 1st line met

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this…
Read more: Breast Her2+ 1st line met
GS-US-592-6238 ASCENT 03

Phase 3

Open and recruiting

Breast TNBC PDL1- 1st line met

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician’s choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell…
Read more: Breast TNBC PDL1- 1st line met
GS-US-592-6173 ASCENT 04

Phase 3

Open and recruiting

Breast TNBC PDL1+ 1st line met

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician’s choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Read more: Breast TNBC PDL1+ 1st line met
GILEAD BREAST GS-US-586-6144

Phase 2

Open and recruiting

Breast TNBC PDL1- 2nd line met

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple-negative breast cancer.
Read more: Breast TNBC PDL1- 2nd line met
EZHI

Phase 1

Open and recruiting

Advanced or metastatic solid tumours – EZH1/2

This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1/2 dual inhibitor, in solid tumors. The study will be conducted in Dose-Escalation and Dose-Expansion parts. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish the MTD or RD for Dose-Expansion part of HM97662 as a…
Read more: Advanced or metastatic solid tumours – EZH1/2
CODEBREAK 202

Phase 3

Open and recruiting

Lung Cancer KRAS G12C

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Read more: Lung Cancer KRAS G12C
CA027 -002

Phase 1, Phase 2

Open and recruiting

Melanoma – BMS986253

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Read more: Melanoma – BMS986253
C4551001

Phase 1

Open and recruiting

Advanced or metastatic solid tumours – PF-07248144

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib or with PF-07220060 + fulvestrant
Read more: Advanced or metastatic solid tumours – PF-07248144